Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of “Moderate Buy” by Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $24.50.

PHAT has been the topic of a number of research analyst reports. Stifel Nicolaus set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, February 26th. Guggenheim lifted their price target on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Barclays raised shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $16.00 to $18.00 in a research note on Friday, March 27th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $27,000. Kestra Advisory Services LLC acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $38,000. Jones Financial Companies Lllp grew its stake in Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after acquiring an additional 2,058 shares during the period. Summit Securities Group LLC acquired a new stake in Phathom Pharmaceuticals during the 1st quarter worth $34,000. Finally, Raymond James Financial Inc. acquired a new stake in Phathom Pharmaceuticals during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock opened at $10.13 on Wednesday. The firm has a 50-day simple moving average of $11.60 and a two-hundred day simple moving average of $13.03. Phathom Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $18.31. The company has a market cap of $807.97 million, a P/E ratio of -4.78 and a beta of 0.51.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.